High absolute bioavailability of methylene blue given as an aqueous oral formulation

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Methylene blue (MB) has recently been reevaluated for malaria treatment.

With the aim of excluding treatment failures due to low bioavailability, the researchers have investigated the absolute bioavailability of MB given as an aqueous oral formulation and its interaction with chloroquine (CQ).

Who Took Part

According to the abstract, 16 individuals were involved.

The age groups tagged for this paper are young adults and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, crossover and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Each person switched between Methylene blue (non-peptide stack partner) and the comparison at some point, usually with a gap in between.

Groups ran in parallel: each of the individuals stayed in one arm throughout.

What Was Measured

The subject headings attached to it are Antimalarials, Area Under Curve, Biological Availability, Chloroquine, Half-Life, Methylene Blue and Plasma.

What This Means in Plain Language

The paper is a randomized, crossover and parallel-group study of Methylene blue (non-peptide stack partner) in 16 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.